Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists

Virginio Salvi, Giancarlo Cerveri, Andrea Aguglia, Salvatore Calò, Mariangela Corbo, Giovanni Martinotti, Gianluca Serafini, Maria Salvina Signorelli, Eugenio Aguglia, Mario Amore, Giovanni Biggio, Guido DI Sciascio, Claudio Mencacci

Research output: Contribution to journalArticle

Abstract

Bipolar disorder (BD) is characterized by recurrent depressive and manic episodes. Lithium, valproate, lamotrigine, and some second-generation antipsychotics (SGAs) are the most typical pharmacological treatments for BD, the main goal being mood stabilization. However, despite these treatments, most patients continue to experience recurrent mood episodes and residual symptoms. Findings from several studies suggest that some SGAs may be beneficial beyond approved indications. The goal of the survey presented in this article was to examine Italian psychiatrists' attitudes concerning the off-label use of SGAs in depressive and maintenance phases of BD. A questionnaire about the off-label prescription of SGAs was e-mailed to 300 psychiatrists from Northern, Central, and Southern Italy affiliated with the Italian Society of Psychopharmacology (SINPF) to investigate the frequency of and motivation for off-label use of SGAs and evaluate the psychiatrists' attitude toward use of specific SGAs in BD; 202 questionnaires were completed. The respondents were equally distributed in terms of sex, and the mean age of respondents was 44.1 years. The majority of the sample reported use of SGAs for off-label indications either very often (16.7%), often (33.7%), or occasionally (34.7%). The main motivation for off-label use of the SGAs was the presence of published evidence (51.5%), followed by patients' nonresponse to previous treatment (37.1%). With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%. For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. In summary, ~50% of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications. Given the relatively limited number of indicated effective treatments for BD, the use of some SGAs off-label may be considered appropriate when dealing with patients whose BD is resistant to medications with labeled indications for BD.

Original languageEnglish
Pages (from-to)318-327
Number of pages10
JournalJournal of Psychiatric Practice
Volume25
Issue number4
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Off-Label Use
Bipolar Disorder
Antipsychotic Agents
Psychiatry
olanzapine
Motivation
Surveys and Questionnaires
Therapeutics
Psychopharmacology
Valproic Acid
Lithium
Italy
Prescriptions

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder : A Survey of Italian Psychiatrists. / Salvi, Virginio; Cerveri, Giancarlo; Aguglia, Andrea; Calò, Salvatore; Corbo, Mariangela; Martinotti, Giovanni; Serafini, Gianluca; Signorelli, Maria Salvina; Aguglia, Eugenio; Amore, Mario; Biggio, Giovanni; DI Sciascio, Guido; Mencacci, Claudio.

In: Journal of Psychiatric Practice, Vol. 25, No. 4, 01.07.2019, p. 318-327.

Research output: Contribution to journalArticle

Salvi, V, Cerveri, G, Aguglia, A, Calò, S, Corbo, M, Martinotti, G, Serafini, G, Signorelli, MS, Aguglia, E, Amore, M, Biggio, G, DI Sciascio, G & Mencacci, C 2019, 'Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists', Journal of Psychiatric Practice, vol. 25, no. 4, pp. 318-327. https://doi.org/10.1097/PRA.0000000000000405
Salvi, Virginio ; Cerveri, Giancarlo ; Aguglia, Andrea ; Calò, Salvatore ; Corbo, Mariangela ; Martinotti, Giovanni ; Serafini, Gianluca ; Signorelli, Maria Salvina ; Aguglia, Eugenio ; Amore, Mario ; Biggio, Giovanni ; DI Sciascio, Guido ; Mencacci, Claudio. / Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder : A Survey of Italian Psychiatrists. In: Journal of Psychiatric Practice. 2019 ; Vol. 25, No. 4. pp. 318-327.
@article{35fbe93ee51c4be2ad92b0aea0929e83,
title = "Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists",
abstract = "Bipolar disorder (BD) is characterized by recurrent depressive and manic episodes. Lithium, valproate, lamotrigine, and some second-generation antipsychotics (SGAs) are the most typical pharmacological treatments for BD, the main goal being mood stabilization. However, despite these treatments, most patients continue to experience recurrent mood episodes and residual symptoms. Findings from several studies suggest that some SGAs may be beneficial beyond approved indications. The goal of the survey presented in this article was to examine Italian psychiatrists' attitudes concerning the off-label use of SGAs in depressive and maintenance phases of BD. A questionnaire about the off-label prescription of SGAs was e-mailed to 300 psychiatrists from Northern, Central, and Southern Italy affiliated with the Italian Society of Psychopharmacology (SINPF) to investigate the frequency of and motivation for off-label use of SGAs and evaluate the psychiatrists' attitude toward use of specific SGAs in BD; 202 questionnaires were completed. The respondents were equally distributed in terms of sex, and the mean age of respondents was 44.1 years. The majority of the sample reported use of SGAs for off-label indications either very often (16.7{\%}), often (33.7{\%}), or occasionally (34.7{\%}). The main motivation for off-label use of the SGAs was the presence of published evidence (51.5{\%}), followed by patients' nonresponse to previous treatment (37.1{\%}). With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46{\%} of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7{\%}. For maintenance treatment of BD, off-label asenapine was considered appropriate by 45{\%} of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1{\%} and 23.8{\%}, respectively. In summary, ~50{\%} of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications. Given the relatively limited number of indicated effective treatments for BD, the use of some SGAs off-label may be considered appropriate when dealing with patients whose BD is resistant to medications with labeled indications for BD.",
author = "Virginio Salvi and Giancarlo Cerveri and Andrea Aguglia and Salvatore Cal{\`o} and Mariangela Corbo and Giovanni Martinotti and Gianluca Serafini and Signorelli, {Maria Salvina} and Eugenio Aguglia and Mario Amore and Giovanni Biggio and {DI Sciascio}, Guido and Claudio Mencacci",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/PRA.0000000000000405",
language = "English",
volume = "25",
pages = "318--327",
journal = "Journal of Psychiatric Practice",
issn = "1527-4160",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder

T2 - A Survey of Italian Psychiatrists

AU - Salvi, Virginio

AU - Cerveri, Giancarlo

AU - Aguglia, Andrea

AU - Calò, Salvatore

AU - Corbo, Mariangela

AU - Martinotti, Giovanni

AU - Serafini, Gianluca

AU - Signorelli, Maria Salvina

AU - Aguglia, Eugenio

AU - Amore, Mario

AU - Biggio, Giovanni

AU - DI Sciascio, Guido

AU - Mencacci, Claudio

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Bipolar disorder (BD) is characterized by recurrent depressive and manic episodes. Lithium, valproate, lamotrigine, and some second-generation antipsychotics (SGAs) are the most typical pharmacological treatments for BD, the main goal being mood stabilization. However, despite these treatments, most patients continue to experience recurrent mood episodes and residual symptoms. Findings from several studies suggest that some SGAs may be beneficial beyond approved indications. The goal of the survey presented in this article was to examine Italian psychiatrists' attitudes concerning the off-label use of SGAs in depressive and maintenance phases of BD. A questionnaire about the off-label prescription of SGAs was e-mailed to 300 psychiatrists from Northern, Central, and Southern Italy affiliated with the Italian Society of Psychopharmacology (SINPF) to investigate the frequency of and motivation for off-label use of SGAs and evaluate the psychiatrists' attitude toward use of specific SGAs in BD; 202 questionnaires were completed. The respondents were equally distributed in terms of sex, and the mean age of respondents was 44.1 years. The majority of the sample reported use of SGAs for off-label indications either very often (16.7%), often (33.7%), or occasionally (34.7%). The main motivation for off-label use of the SGAs was the presence of published evidence (51.5%), followed by patients' nonresponse to previous treatment (37.1%). With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%. For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. In summary, ~50% of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications. Given the relatively limited number of indicated effective treatments for BD, the use of some SGAs off-label may be considered appropriate when dealing with patients whose BD is resistant to medications with labeled indications for BD.

AB - Bipolar disorder (BD) is characterized by recurrent depressive and manic episodes. Lithium, valproate, lamotrigine, and some second-generation antipsychotics (SGAs) are the most typical pharmacological treatments for BD, the main goal being mood stabilization. However, despite these treatments, most patients continue to experience recurrent mood episodes and residual symptoms. Findings from several studies suggest that some SGAs may be beneficial beyond approved indications. The goal of the survey presented in this article was to examine Italian psychiatrists' attitudes concerning the off-label use of SGAs in depressive and maintenance phases of BD. A questionnaire about the off-label prescription of SGAs was e-mailed to 300 psychiatrists from Northern, Central, and Southern Italy affiliated with the Italian Society of Psychopharmacology (SINPF) to investigate the frequency of and motivation for off-label use of SGAs and evaluate the psychiatrists' attitude toward use of specific SGAs in BD; 202 questionnaires were completed. The respondents were equally distributed in terms of sex, and the mean age of respondents was 44.1 years. The majority of the sample reported use of SGAs for off-label indications either very often (16.7%), often (33.7%), or occasionally (34.7%). The main motivation for off-label use of the SGAs was the presence of published evidence (51.5%), followed by patients' nonresponse to previous treatment (37.1%). With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%. For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. In summary, ~50% of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications. Given the relatively limited number of indicated effective treatments for BD, the use of some SGAs off-label may be considered appropriate when dealing with patients whose BD is resistant to medications with labeled indications for BD.

UR - http://www.scopus.com/inward/record.url?scp=85069575869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069575869&partnerID=8YFLogxK

U2 - 10.1097/PRA.0000000000000405

DO - 10.1097/PRA.0000000000000405

M3 - Article

C2 - 31291215

AN - SCOPUS:85069575869

VL - 25

SP - 318

EP - 327

JO - Journal of Psychiatric Practice

JF - Journal of Psychiatric Practice

SN - 1527-4160

IS - 4

ER -